⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights

Company

CRO Partners
Contact Us
Privacy Policy

© 2026 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Efruxifermin (Efruxifermin) | Accelerate Your Fibrosis Research

Home/Drugs/Efruxifermin

Efruxifermin

Efruxifermin

Phase 3

Sponsor: Akero Therapeutics

Indication: MASH

Mechanism of Action

FGF21 Analog

Target: FGF21

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT04767529

A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

Phase:PHASE2Org:Akero Therapeutics, Inc

COMPLETED

Relevant Publications (PubMed)

Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Cirrhosis Clinical Trials: Lessons Learned and Future Directions.

Patil R, Dunn W, Noureddin M et al.

Drugs2026 Mar 14

Efficacy and Safety of Efruxifermin in Patients With MASH: A Meta-Analysis of Randomized Controlled Trials.

Gastroenterol Hepatol (N Y)2025 Nov

Network Meta-Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution.

Souza M, Al-Sharif L, Antunes VLJ et al.

Aliment Pharmacol Ther2026 Apr

Efficacy and safety of fibroblast growth factor 21 analogs in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and network meta-analysis.

Validated Models

This drug has been validated in the following preclinical models:

NCT03976401

A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

Phase:PHASE2Org:Akero Therapeutics, Inc

ACTIVE_NOT_RECRUITINGNCT06161571

A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Phase:PHASE3Org:Akero Therapeutics, Inc

RECRUITINGNCT06215716

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Phase:PHASE3Org:Akero Therapeutics, Inc

ACTIVE_NOT_RECRUITINGNCT05039450

A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)

Phase:PHASE2Org:Akero Therapeutics, Inc

View all trials on ClinicalTrials.gov

Abdeljawad MM, Hasan MT, Fareed A et al.

J Pharmacol Exp Ther2026 Jan

Disease-modifying effect of efruxifermin in compensated cirrhosis due to MASH: To miss the forest for the tree(s).

Mandorfer M, Semmler G

JHEP Rep2025 Dec

View more on PubMed